Corrigendum to Epigenetically Reactivating Adhesion GPCR B1 as a Brain Cancer Therapy (Abstract ID: 234961): The Journal of Pharmacology and Experimental Therapeutics Volume 393, Issue 5, Supplement (2026), 104001
Publication date: November 2026 Source: The Journal of Pharmacology and Experimental Therapeutics, Volume 393, Issue 11 Author(s): J. Stillwell, M. Ahmadian Elmi, E. Van Meir
Corrigendum to Epigenetically Reactivating Adhesion GPCR B1 as a Brain Cancer Therapy (Abstract ID: 234961): The Journal of Pharmacology and Experimental Therapeutics Volume 393, Issue 5, Supplement (2026), 104001. // The Journal of Pharmacology and Experimental Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S0022356526012498?dgcid=rss_sd_all
Corrigendum to Epigenetically Reactivating Adhesion GPCR B1 as a Brain Cancer Therapy (Abstract ID: 234961): The Journal of Pharmacology and Experimental Therapeutics Volume 393, Issue 5, Supplement (2026), 104001. The Journal of Pharmacology and Experimental Therapeutics. https://www.sciencedirect.com/science/article/pii/S0022356526012498?dgcid=rss_sd_all
“Corrigendum to Epigenetically Reactivating Adhesion GPCR B1 as a Brain Cancer Therapy (Abstract ID: 234961): The Journal of Pharmacology and Experimental Therapeutics Volume 393, Issue 5, Supplement (2026), 104001.” The Journal of Pharmacology and Experimental Therapeutics.
@article{article32413,
title = {Corrigendum to Epigenetically Reactivating Adhesion GPCR B1 as a Brain Cancer Therapy (Abstract ID: 234961): The Journal of Pharmacology and Experimental Therapeutics Volume 393, Issue 5, Supplement (2026), 104001},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S0022356526012498?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...